Stockscreener 앱 받기
22.95
3.45%
-0.82
시간 외 거래:
22.95
전일 마감가:
$23.77
열려 있는:
$24.49
하루 거래량:
145.91K
Relative Volume:
5.16
시가총액:
$947.39M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+14.64%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$22.41
$24.50
1주일 범위
$18.62
$24.50
52주 변동 폭
$18.62
$24.50
Septerna Inc Stock (SEPN) Company Profile
Septerna Inc 주식(SEPN)의 최신 뉴스
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering - ForexTV.com
Ra Capital Management buys $75 million in Septerna stock - Investing.com
Ra Capital Management buys $75 million in Septerna stock By Investing.com - Investing.com UK
IPO Radar: Septerna, Swiggy and Horizon Robotics - The Armchair Trader
Septerna sees $11.7 million in stock purchases by Third Rock Ventures - Investing.com South Africa
IPO Roundup: Brazil Potash, Septerna and more (NYSEARCA:IPO) - Seeking Alpha
Septerna proposes terms for upsized $175M IPO - MSN
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names - Seeking Alpha
Septerna’s GPCRs draw strong demand in $288M IPO - BioCentury
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Hedge Funds, Asset Managers Turn Dollar Bulls on Election Risks - Yahoo Finance
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
Septerna Shares Rise 29% on First Trading Day - MarketWatch
Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs - MedCity News
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut - KFGO
Septerna Shares Jump 42% After IPO Shows Biotech Still Hot - AllSides
Goodwin, Cooley Guide Septerna's Upsized $288M IPO - Law360
Septerna's $288M IPO is another sign of the market warming to biotech investment - Fierce Biotech
Septerna Rings the Opening Bell - Nasdaq
MicroStrategy Touches New Highs as Trading Volume Relative to Nvidia Surges - Yahoo Finance
Septerna Prices Upsized 16M Share IPO at $18/sh By Investing.com - Investing.com Nigeria
Septerna Prices Upsized 16M Share IPO at $18/sh - Investing.com
Septerna Shares Set for Trading Debut After Upsized IPO - MarketWatch
Goldman-backed drug developer Septerna raises $288mln in US IPO - ZAWYA
GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive
Goldman-backed drug developer Septerna raises $288 mln in US IPO - Reuters
Septerna Prices Upsized Initial Public Offering - The Manila Times
SEPNSepterna, Inc. Latest Stock News & Market Updates - StockTitan
TSX Smallcap Index (TXTW) QuotePress Release - The Globe and Mail
S&P Midcap 400 (IDX) QuotePress Release - The Globe and Mail
Yorvipath-finders? Septerna, others forge on in hypothyroidism - BioWorld Online
Goldman-backed drug developer Septerna targets $743 million valuation in upsized US IPO - MSN
Septerna Files for 15.28M Share IPO at $18/sh By Investing.com - Investing.com Canada
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO - XM
7 Recent and Upcoming IPOs in 2024 - MSN
TSX 60 Carbon Price Risk 2030 Adj Index (TXCP) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Septerna proposes terms for upsized $175M IPO (Pending:SEPN) - Seeking Alpha
Septerna Readies $175 Million IPO Plan For Endocrine And Immune Disease Treatments (Pending:SEPN) - Seeking Alpha
TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail
Goodwin Steers Biotech Firm Septerna's Plans For $175M IPO - Law360
Biotech Septerna aims to raise up to $186 million in US IPO - WKZO
Goldman-backed biotech Septerna targets $628 mln valuation in US IPO - Reuters
Goldman-backed biotech Septerna targets $628 million valuation in US IPO - MSN
Septerna Inc (SEPN) 재무 분석
Septerna Inc (SEPN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):